

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/026,335
Filing Date	December 21, 2001
First Named Inventor	Pillarsetti, S.
Art Unit	1644
Examiner Name	Saunders, David A.
Attorney Docket Number	R18631 1030.1 (51880.0006.2)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>dal</i>	1	MARUI, N. et al., Vascular Cell Adhesion Molecule-1 (VCAM-1) Gene Transcription and Expression are Regulated through an Antioxidant-sensitive Mechanism in Human Vascular Endothelial Cells, The American Society for Clinical Investigation, Inc., Oct. 1993, Vol. 92, 1866-1874	
<i>J</i>	2	SCHRECK, R. et al., Dithiocarbamates as Potent Inhibitors of Nuclear Factor kB Activation in Intact Cells, J. Exp. Med., The Rockefeller University Press, May 1992, Vol. 175, 1181-1194	
<i>↓</i>	3	NEUMANN, A. et al., Pro-Inflammatory Effects of AGEs: AGE-Induced Transduction in Macrophages, Journal of the American Society of Nephrology, Sept. 2000, 485A, Vol. 11, American Society of Nephrology, U.S.A.	

Examiner Signature	<i>David A. Saunders</i>	Date Considered	7/23/06
--------------------	--------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/026,335
		Filing Date	December 21, 2001
		First Named Inventor	Pillarisetti, S.
		Art Unit	1644
Examiner Name	Saunders, David A.		
Attorney Docket Number	R18631 1030.1 (51880.0006.2)		
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	MARUI, N. et al., Vascular Cell Adhesion Molecule-1 (VCAM-1) Gene Transcription and Expression are Regulated through an Antioxidant-sensitive Mechanism in Human Vascular Endothelial Cells, The American Society for Clinical Investigation, Inc., Oct. 1993, Vol. 92, 1866-1874	
	2	SCHRECK, R. et al., Dithiocarbamates as Potent Inhibitors of Nuclear Factor KB Activation in Intact Cells, J. Exp. Med., The Rockefeller University Press, May 1992, Vol. 175, 1181-1194	
	3	NEUMANN, A. et al., Pro-inflammatory Effects of AGEs: AGE-Induced Transduction in Macrophages, Journal of the American Society of Nephrology, Sept. 2000, 485A, Vol. 11, American Society of Nephrology, U.S.A.	

Examiner Signature	<i>David A. Saunders</i>	Date Considered	7/23/06
-----------------------	--------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.